Terms: = Germ cell tumor AND SET, I2PP2A, 6418, ENSG00000119335, TAF-IBETA, PHAPII, IGAAD, 2PP2A AND Treatment
1496 results:
1. Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanoma.
Versluis JM; Blankenstein SA; Dimitriadis P; Wilmott JS; Elens R; Blokx WAM; van Houdt W; Menzies AM; Schrage YM; Wouters MWJM; Sanders J; Broeks A; Scolyer RA; Suijkerbuijk KPM; Long GV; Akkooi ACJV; Blank CU
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38677880
[TBL] [Abstract] [Full Text] [Related]
2. Survival Outcome Prediction in Glioblastoma: Insights from MRI Radiomics.
Styliara EI; Astrakas LG; Alexiou G; Xydis VG; Zikou A; Kafritsas G; Voulgaris S; Argyropoulou MI
Curr Oncol; 2024 Apr; 31(4):2233-2243. PubMed ID: 38668068
[No Abstract] [Full Text] [Related]
3. Experimentally validated oxidative stress -associated prognostic signatures describe the immune landscape and predict the drug response and prognosis of SKCM.
Rong D; Su Y; Jia D; Zeng Z; Yang Y; Wei D; Lu H; Cao Y
Front Immunol; 2024; 15():1387316. PubMed ID: 38660305
[TBL] [Abstract] [Full Text] [Related]
4. A multi-omics analysis-based model to predict the prognosis of low-grade gliomas.
Du Z; Jiang Y; Yang Y; Kang X; Yan J; Liu B; Yang M
Sci Rep; 2024 Apr; 14(1):9427. PubMed ID: 38658591
[TBL] [Abstract] [Full Text] [Related]
5. Expression of STAT3 and hypoxia markers in long-term surviving malignant glioma patients.
Dvorakova K; Skarkova V; Vitovcova B; Soukup J; Vosmikova H; Pleskacova Z; Skarka A; Bartos MC; Krupa P; Kasparova P; Petera J; Rudolf E
BMC Cancer; 2024 Apr; 24(1):509. PubMed ID: 38654280
[TBL] [Abstract] [Full Text] [Related]
6. Prediction of High-Risk Neuroblastoma Among Neuroblastic tumors Using Radiomics Features Derived from Magnetic Resonance Imaging: A Pilot Study.
Kim J; Choi YH; Yoon H; Lim HJ; Han JW; Lee MJ
Yonsei Med J; 2024 May; 65(5):293-301. PubMed ID: 38653568
[TBL] [Abstract] [Full Text] [Related]
7. Influence of Post-radiation Ocular Surface Disorder on Ocular Surgery: A Case Report and Review of the Literature.
Gjukaj D; Morina I; Valmaggia C; Ammann D; Todorova MG
Klin Monbl Augenheilkd; 2024 Apr; 241(4):421-425. PubMed ID: 38653304
[TBL] [Abstract] [Full Text] [Related]
8. Has-miR-199a-3p/RELA/SCD inhibits immune checkpoints in AMD and promotes macrophage-mediated inflammation and pathological angiogenesis through lipid metabolism pathway: A computational analysis.
Jiang J; Wang S; Li Y; Wang Y; Liao R
PLoS One; 2024; 19(4):e0297849. PubMed ID: 38625951
[TBL] [Abstract] [Full Text] [Related]
9. Pathway-based stratification of gliomas uncovers four subtypes with different TME characteristics and prognosis.
Huang R; Han B; Zhang Y; Yang J; Wang K; Liu X; Wang Z
J Cell Mol Med; 2024 Apr; 28(8):e18208. PubMed ID: 38613347
[TBL] [Abstract] [Full Text] [Related]
10. A comprehensive analysis of the KLRB1 expression and its clinical implication in testicular germ cell tumors: A review.
Li L; Hu Y; Li X; Ju B
Medicine (Baltimore); 2024 Apr; 103(15):e37688. PubMed ID: 38608099
[TBL] [Abstract] [Full Text] [Related]
11. Signature Construction and Disulfidptosis-Related Molecular Cluster Identification for Better Prediction of Prognosis in Glioma.
Zhuang Y; Chen J; Mai Z; Huang W; Zhong W
J Mol Neurosci; 2024 Apr; 74(2):38. PubMed ID: 38573391
[TBL] [Abstract] [Full Text] [Related]
12. Analyses of tertiary lymphoid structures observed in cases of Merkel cell carcinoma showing spontaneous regression.
Nakamura M; Yoshimitsu M; Magara T; Kano S; Kato H; Morita A
Exp Dermatol; 2024 Mar; 33(3):e15062. PubMed ID: 38532566
[TBL] [Abstract] [Full Text] [Related]
13. Novel prognostic biomarker TBC1D1 is associated with immunotherapy resistance in gliomas.
Song D; Yang Q; Li L; Wei Y; Zhang C; Du H; Ren G; Li H
Front Immunol; 2024; 15():1372113. PubMed ID: 38529286
[TBL] [Abstract] [Full Text] [Related]
14. A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma.
Wei X; Zou Z; Zhang W; Fang M; Zhang X; Luo Z; Chen J; Huang G; Zhang P; Cheng Y; Liu J; Liu J; Zhang J; Wu D; Chen Y; Ma X; Pan H; Jiang R; Liu X; Ren X; Tian H; Jia Z; Guo J; Si L
Eur J Cancer; 2024 May; 202():114008. PubMed ID: 38479118
[TBL] [Abstract] [Full Text] [Related]
15. Identification of Key Molecular Pathways and Associated Genes as Targets to Overcome Radiotherapy Resistance Using a Combination of Radiotherapy and Immunotherapy in Glioma Patients.
Zhang T; Zhang Q; He X; Lu Y; Shao A; Sun X; Shao Y
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474320
[TBL] [Abstract] [Full Text] [Related]
16. Risk factors, prognostic factors, and nomograms for distant metastases in patients with gastroenteropancreatic neuroendocrine tumors: a population-based study.
Li X; Fan Y; Tong J; Lou M
Front Endocrinol (Lausanne); 2024; 15():1264952. PubMed ID: 38449852
[TBL] [Abstract] [Full Text] [Related]
17. D-2-HG Inhibits IDH1mut Glioma Growth via FTO Inhibition and Resultant m6A Hypermethylation.
Pianka ST; Li T; Prins TJ; Eldred BSC; Kevan BM; Liang H; Zapanta Rinonos S; Kornblum HI; Nathanson DA; Pellegrini M; Liau LM; Nghiemphu PL; Cloughesy TF; Lai A
Cancer Res Commun; 2024 Mar; 4(3):876-894. PubMed ID: 38445960
[TBL] [Abstract] [Full Text] [Related]
18. Suppression of ITPKB degradation by Trim25 confers TMZ resistance in glioblastoma through ROS homeostasis.
Yan Y; Zhou S; Chen X; Yi Q; Feng S; Zhao Z; Liu Y; Liang Q; Xu Z; Li Z; Sun L
Signal Transduct Target Ther; 2024 Mar; 9(1):58. PubMed ID: 38438346
[TBL] [Abstract] [Full Text] [Related]
19. Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches.
Lofiego MF; Piazzini F; Caruso FP; Marzani F; Solmonese L; Bello E; Celesti F; Costa MC; Noviello T; Mortarini R; Anichini A; Ceccarelli M; Coral S; Di Giacomo AM; Maio M; Covre A;
J Transl Med; 2024 Mar; 22(1):223. PubMed ID: 38429759
[TBL] [Abstract] [Full Text] [Related]
20. DNA Methylation Signatures Correlate with Response to Immune Checkpoint Inhibitors in Metastatic Melanoma.
Ressler JM; Tomasich E; Hatziioannou T; Ringl H; Heller G; Silmbrod R; Gottmann L; Starzer AM; Zila N; Tschandl P; Hoeller C; Preusser M; Berghoff AS
Target Oncol; 2024 Mar; 19(2):263-275. PubMed ID: 38401029
[TBL] [Abstract] [Full Text] [Related]
[Next]
